Allworth Financial LP Has $3.35 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Allworth Financial LP raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,953 shares of the biopharmaceutical company’s stock after buying an additional 7,143 shares during the quarter. Allworth Financial LP’s holdings in Gilead Sciences were worth $3,345,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in GILD. Principal Securities Inc. increased its holdings in shares of Gilead Sciences by 45.0% in the fourth quarter. Principal Securities Inc. now owns 14,404 shares of the biopharmaceutical company’s stock worth $1,330,000 after acquiring an additional 4,468 shares in the last quarter. Everhart Financial Group Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $239,000. Roxbury Financial LLC bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $88,000. Roman Butler Fullerton & Co. bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $298,000. Finally, AustralianSuper Pty Ltd increased its holdings in shares of Gilead Sciences by 0.5% in the fourth quarter. AustralianSuper Pty Ltd now owns 1,138,269 shares of the biopharmaceutical company’s stock worth $105,142,000 after acquiring an additional 5,989 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. Wells Fargo & Company increased their price target on Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Wolfe Research assumed coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Mizuho increased their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Thursday, February 13th. Eleven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $101.33.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $104.08 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $106.69. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50-day simple moving average of $93.87 and a two-hundred day simple moving average of $87.70. The stock has a market capitalization of $129.71 billion, a price-to-earnings ratio of 1,156.44, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Analysts forecast that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 3.04%. Gilead Sciences’s payout ratio is presently 3,422.22%.

Insider Activity

In related news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 710,500 shares of company stock worth $67,684,956. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.